[Study progress on serogroup B meningococcal vaccine].
Meningococcal disease, caused by Neisseria meningitidis (Nm), is still one serious threatening infectious disease with high mortality. Vaccination is available for prevention and control of such disease. Based on the chemical structure of capsule polysaccharide, Nm strains were classified into 13 serogroups. Meningococcal polysaccharide vaccines and polysaccharide conjugated protein vaccine against serogroup A, C, W135 and Y were efficacious and have been widely used. Because of poor immunogenicity and the structurally homologous with neural cell, capsule polysaccharide of serogroup B Nm can not be used as vaccine candidate. In last several decades, B group vaccines develoment focused on the proteins research. Based on the out membrane protein and reverse vaccinology technology, progress of B group vaccine were accelerated. Several meningococcal B vaccine showed favorable immunogenicity and efficacity. Some B vaccines have been licensed and widely used.
Shao
Zhu-jun
ZJ
Institute of Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Li
Yi-xing
YX
D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D002462:Cell Membrane / Q000276:immunology; D006801:Humans; D008585:Meningitis, Meningococcal / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology
D001425:Bacterial Outer Membrane Proteins; D022401:Meningococcal Vaccines